Ahmad highlights concerns about regulatory agencies like the FDA and MHRA acting more as enablers for the pharmaceutical industry than as protectors of public health. Kim points out the troubling reliance on industry fees for funding, raising questions about the integrity of these organizations. Together, they explore the implications of these dynamics on drug approval processes and public safety.
